Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Bernard Escudier(Institut Gustave Roussy), Piotr Tomczak(Poznan University of Medical Sciences), Thomas E. Hutson(Texas Oncology), M. Dror Michaelson(Massachusetts General Hospital), Sylvie Négrier(Centre Léon Bérard), Stéphane Oudard(Université Paris Cité), Martin Gore(Royal Marsden Hospital), Jamal Tarazi(Pfizer (United States)), Subramanian Hariharan(Pfizer (United States)), Connie Chen(Pfizer (United States)), Brad Rosbrook(Pfizer (United States)), Sinil Kim(Pfizer (United States)), Brian I. Rini(Cleveland Clinic)
Cited by 745
Abstract
Related Papers
No related papers found
Powered by citation graph analysis